Clinical trials: Monotherapy After PCI, open to volunteers
Coronary Artery Disease
Ticagrelore Alone Post PCI
After PCI for CCS patients, single center double blind randomization will be done and patients will receive aspirin 80 mg and clopidogrel 75 mg versus 90 mg two times daily of ticagrelor, for 6 months and MACE will be followed in…
- Trial name
- TICALONE (NCT06509893)
- Testing
- aspirin 80 mg and clopidogrel 75 mg daily, Ticagrelor 90 MG
- Where
- 2 sites in Iran
- Volunteers
- 5,400 people
- Sponsor
- Shiraz University of Medical Sciences
Acute Coronary Syndrome, Percutaneous Coronary Intervention
Sequential MonotherApy of TicagrElor and Clopidogrel After Coronary Intervention
The MATE study is a randomized, multicenter, open-label, investigator-initiated clinical trial aimed to evaluate efficacy and safety of sequential monotherapy of ticagrelor and clopidogrel in patients with acute coronary syndrome…
- Trial name
- MATE (NCT04937699)
- Testing
- Standard-DAPT of Ticagrelor plus aspirin, Sequential monotherapy of Ticagrelor and clopidogrel
- Where
- China
- Volunteers
- 2,690 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Coronary Artery Disease
The PIONEER-IV Study is Comparing Clinical Outcomes Between Angiography-derived Physiology Guidance to Usual Care in an All-comers PCI Population With Unrestrictive Use of the HT Supreme Sirolimus-eluting Stent
PIONEER-IV is a prospective, single-blind (patient), randomized, 1:1, controlled, multi-center study comparing clinical outcomes between angiography-derived physiology guidance to LRDP and usual care in an all-comers patient…
- Trial name
- PIONEER-IV (NCT04923191)
- Testing
- Angiography-derived physiology guidance/Local routine diagnostic procedure (LRDP) and usual care
- Where
- 19 sites in Belgium, Ireland and 3 more
- Volunteers
- 2,540 people
- Sponsor
- National University of Ireland, Galway, Ireland
ST-segment Elevation Myocardial Infarction (STEMI)
Bivalirudin with Prolonged Infusion During PCI Versus Heparin After Fibrinolytic Therapy
This multicenter, randomized controlled trial in China aims to enroll 2,400 patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention (PCI) within 24 hours post-fibrinolysis.
- Trial name
- BRIGHT-FIT (NCT06861374)
- Testing
- Bivalirudin, Unfractionated heparin
- Volunteers
- 2,400 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Coronary Artery Disease, Percutaneous Coronary Intervention
Study of the Long-term Effects of P2Y12 Inhibitor Monotherapy and Coagulation Markers After Percutaneous Coronary Angioplasty.
Patients who undergo percutaneous coronary intervention (PCI) are commonly treated with antiplatelet therapy to prevent stent thrombosis and recurrence of events.
- Conditions
- Coronary Artery Disease, Percutaneous Coronary Intervention, Acute Coronary Syndromes, Antiplatelet Therapy
- Trial name
- HI-TECH 2 (NCT07582835)
- Testing
- Clopidogrel, Ticagrelor, Prasugrel
- Where
- Switzerland
- Volunteers
- 355 people
- Sponsor
- Cardiocentro Ticino
Coronary Arterial Disease (CAD), Percutaneous Coronary Intervention (PCI)
Prasugrel Monotherapy Reduced Dose in Acute and Chronic Coronary Syndrome Patients After Percutaneous Coronary Intervention (PROMOTE)
Rationale: Dual antiplatelet therapy, consisting of aspirin and a P2Y12-inhibitor, reduces the risk of stent-related and non-stent-related ischemic events after percutaneous coronary intervention (PCI).
- Trial name
- PROMOTE (NCT06916520)
- Testing
- Prasugrel 5 mg, Dual Antiplatelet (DAPT) Therapy
- Where
- Netherlands
- Volunteers
- 300 people
- Sponsor
- J.P.S Henriques
Coronary Artery Disease Requiring Coronary Revascularization With Newer Generation DES Implantation
Effect of High-intensity Statin With Ezetimibe COmbination theRapy Versus High-intensity sTatin Monotherapy After Percutaneous Coronary Intervention With Drug-eluting Stents; the ESCORT Trial
This study sought to evaluate whether ezetimibe combination to high-intensity statin therapy will have more prominent beneficial effect compared to high-intensity statin monotherapy in patients who underwent coronary…
- Trial name
- NCT05782777
- Testing
- ezetimibe/high-intensity statin combination therapy (ezetimibe 10mg plus atoravastatin 40mg), high-intensity statin monotherapy (atoravastatin 40mg)
- Where
- South Korea
- Volunteers
- 4,310 people
- Sponsor
- Yonsei University
ST-segment Elevation Myocardial Infarction (STEMI)
PRasugrEl Monotherapy Following prImary percUtaneous Coronary Intervention for ST-elevation Myocardial Infarction
The aim of this study is to evaluate the safety of prasugrel monotherapy without aspirin versus 12-month dual antiplatelet therapy (DAPT) in patients with STEMI using platinum-chrome everolimus-eluting stent (PtCr-EES: SYNERGYTM).
- Trial name
- PREMIUM (NCT05709626)
- Testing
- No aspirin (Prasugurel monotherapy), 12-month DAPT
- Where
- Japan
- Volunteers
- 2,258 people
- Sponsor
- Kindai University